Who are low dose capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Erlotinib, Pemetrexed, Unitrim, Irinotecan, 5FU, leucovorin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

low dose capecitabine — Competitive Intelligence Brief

low dose capecitabine (low dose capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite. Area: Oncology.

phase 3 Antimetabolite Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

low dose capecitabine (low dose capecitabine) — Lund University Hospital. Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
low dose capecitabine TARGET	low dose capecitabine	Lund University Hospital	phase 3	Antimetabolite	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Unitrim	BRODIMOPRIM		marketed	brodimoprim	Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite class)

Grupo Espanol Multidisciplinario del Cancer Digestivo · 2 drugs in this class
NRG Oncology · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Centre Oscar Lambret · 1 drug in this class
Iwate Medical University · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low dose capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab